Risk factor of diabetic nephropathy in adults. Bibliography update
Keywords:
Nephropathy, Hyperglycemia, Insufficiency, BiomarkersAbstract
Diabetic nephropathy is a chronic complication of diabetes mellitus, characterized by decreased glomerular filtration due to several risk factors, mainly hyperglycemia and renal hypertension, causing chronic renal failure, with significant morbidity and mortality. This process is the product of pathophysiological mechanisms that generate changes at the micro and macroscopic level in the kidney, causing irreparable damage in advanced stages. Therefore, its early diagnosis is of vital importance to avoid its appearance. The most used biomarkers for its detection are serum creatinine, microalbuminuria and glomerular filtration rate. This pathology is the reason for several studies at a global and national level, in which the different biomarkers are compared for an initial and timely detection, due to the high costs it generates for the health system.
Downloads
References
Varghese R, Jialal I. Diabetic Nephropathy Stat Pearls. [Online]; 2022. Acceso 6 de Enerode 2022. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK534200/.
Selby N, Taal M. An updated overview of diabetic nephropathy: Diagnosis, prognosis, treatment goals and latest guidelines. Diabetes Obesity and Metabolism. 2020; 22(51).
Wang JS, Yen FS. Epidemiological characteristics of diabetic kidney disease in Taiwan. Journal od diabtes Investogation. 2021; 12(12).
Lugmaña G, Carrera S, Alban A. Registro Estadístico de Defunciones Generales. Boletín. Guayaquil: Instituto Nacional de Estadistica y Censos (INEC), Dirección de Estadísticas Sociodemográficas.Boletín técnico N° -XX-Año-OE.
Bernal J, Cordero M. Prevalencia de la nefropatía diabética en la nueva categorización de diabetes mellitus en adultos con diabetes mellitus tipo 2, en el laboratorio HORMOLAB en la ciudad de Cuenca-Ecuador, 2019: un análisis epidemiológico. En: Cuenca; 2021 p. 1-29.
Ilyas Z, Chaiban J, Kricorian A. Novel insights into the pathophysiology and clinical aspects of diabetic nephropathy. Endocr Metab Disord. 2017; 18(21-28).
Gutierrez Montenegro L, Ortiz Peralta D D, Bueno. ACE. [Online]; 2021. Acceso 22 de Marzode 2022. Disponible en: http://revistaendocrino.org/index.php/rcedm/article/view/698.
Kausik U, Lewis J. Update on Diabetic Nephropathy: Core Curriculum 2018. AJKD. 2018; 71(6).
Chih Lin Y, Hsing Chang Y, Yu Yang S, Dun Wu K, Shinn Chu T. Uptodate of pathophysiology and management of diabetic kidney disease. Journal of the formosan Medical Association. 2018; 117(662-675).
Barrera Chimal J, Jaisser. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets. Diabetes Obesity and Metabolism. 2020; 22(1).
Salanova Villanueva L, Santos Sanchez B, Sanz Sain. Mecanismos inflamatorios y fibróticos en la enfermedad renal. Protagonistas y terapéutica. Lab Clin. 2018; 11(4).
Meza C, San Martin Ojeda C, Ruiz J, Frugone C. Pathophysiology of diabetic nephropathy: a literature review. Medwave. 2017; 1(16).
Guzmán Hernández E, Segura Cobos D. Mecanismos de inducción de la matriz extracelular en la nefropatía diabética.. Cubana Endocrinol. 2015; 26(3).
Zhu Y, Liang Li Z, Ding A, Yang H, Ping Zhu W, Xia. Olmesartan Medoxomil, An Angiotensin II-Receptor Blocker, Ameliorates Renal Injury In db/db Mice. Drug Des Devel Ther. 2019; 13(3657-3667).
Gurley S, Ghosh S, Jhonson S, Azushima K, Binte Sa. Inflammation and Immunity Pathways Regulate Genetic Susceptibility to Diabetic. American Diabetes Association. 2018; 67(10).
Sugita E, Hayashi K, Hishikawa A, Itoh H. Epigenetic Alterations in Podocytes in Diabetic Nephropathy. Front Pharmacol. 2021; 12(75).
Zhang L, Wen Z, Han L, Zheng Y, Wei Y, Wang X, et al. Research Progress on the Pathological Mechanisms of Podocytes in Diabetic Nephropathy. J Diabetes Res. 2020; 2020(7504798).
Wan S, Wan S, Jiao X, Cao X, Gu Y, Yan L, et al. Advances in understanding the innate immune-associated diabetic kidney disease. The FASEB Journal. 2020; 35(1367).
Gorriz J, Terrádez L. Clínica y Anatomía Patológica de la Nefropatía. Nefrologia al dia. 2021.
Di Vincenzo A, Bettini S, Russo Lea. Renal structure in type 2 diabetes: facts and misconceptions. J Nephrol. 2020; 33.
Raja P, Maxwell A, Brazil D. The Potential of Albuminuria as a Biomarker of Diabetic Complications. Cardiovasc Drugs Ther. 2021; 35.
Khan M. Diabetic nephropathy: recent advances in pathophysiology and challenges in dietary management. Diabetol Metab Syndr. 2019; 11(7).
Comai G, Malvi DAA, Vasuri F, Valente S, Ambrosi F, Capelli I, et al. Histological Evidence of Diabetic Kidney Disease Precede Clinical Diagnosis. American journal of nephrology. 2019; 50(1).
Garnica J, Lavalle F, Magaña J, Almeda P, Cetina J, Chavez J, et al. Consensus document on the use of iSGLT2 in the treatment of patients with type 2 diabetes mellitus. Gaceta Medica de Mexico. 2022; 28(158).
Fernandez B, Ortiz A. Biomarcadores en enfermedad renal diabética: 10 respuestas que un nefrólogo debe conocer. Nefroplus. 2020; 12(1).
Garcia M, Coll E, Pedret S, Bermudo C, Cardenas M, Cortes M, et al. Cistatina C en la evaluación de la función renal. Revista del Laboratorio Clinico. 2011; 4(1).
Solis , Benavides G, Vásconez E, Campoverde A. Correlación de cistatina “C” y creatinina sérica frente al filtrado glomerular en pacientes con nefropatía diabética. Revista Médica Científica CAMbios. 2020; 19(1).
Prego E, Serrano M, Pita Y, Madrazo MdC. Marcadores Bioquímicos Tempranos en el Diagnostico de la Nefropatía Diabética. Panorama. Cuba y Salud. 2018; 13(523-527).
Castillo E. Medicina de estilos de vida aplicado a complicaciones tardías de la diabetes mellitus. Reporte de caso. Revista de la Facultad de Medicina Humana. 2022; 22(1).
Roy S, Schweiker O, Behjath J, Miller R, Raju R, O"Neill L, et al. Risk Factors and Comorbidities Associated with Diabetic Kidney Disease. Journal of Primary Care&Community Health. 2021; 12(1-10).
San Blas JC, Morffi L, Figueredo N, Diaz A, Fergunson Y, Viera Y. Marcadores de daño renal y progresión de la insuficiencia renal crónica en el adulto mayor. REVISTA MÉDICA ELECTRÓNICA DE CIEGO DE ÁVILA. 2022; 28(3068).
Viejo I, Tabernero G. Factores de riesgo y progresión a tratamiento renal sustitutivo de la nefropatía diabética. Nefroplus. 2019; 11(02).
Su W, Cao R, Cheng He Y, Fei Guan Y, Zhong Ruan X. Crosstalk of Hyperglycemia and Dyslipidemia in Diabetic Kidney Disease. Kidney diseases. 2017; 3(171-180).
Hussain S, Chand Jamali M, Habib A, Mohd Akntar SH, Kalam Najmi A. Diabetic kidney disease: An overview of prevalence, risk factors, and biomarkers. Clinical Epidemiology and Global Health. 2020; 9(2-1).
Jiang W, Wang J, Shen X, Lu W, Wang Y, Li W, et al. Establishment and Validation of a Risk Prediction Model for Early Diabetic Kidney Disease Based on a Systematic Review and Meta-Analysis of 20 Cohorts. Diabetes Care. 2020; 4(43).
Alicic R, Rooney M, Tutle K. Diabetic Kidney Disease. Clinical Journal of American Society of Nephrology. 2017; 12(12).
Saxena N, Gupta B, Goyal J. Assessment of risk factors for diabetic nephropathy among newly diagnosed Type 2 diabetic subjects: A pilot study. European Journal of Molecular & Clinical Medicine. 2020; 7(11).
Rocco M, Berns J. KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update. American Journal of Kidney Diseases. 2012; 60(850-86).
Seck S, Doupa D, Ahou S, Gueye S, Engerran M, Gueye L. Prevalence and Associated Factors of Diabetic Kidney Disease in Senegalese Patients: A Cross-Sectional Study in Saint-Louis. Scientific Research. 2020; 10(1).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 AVFT – Archivos Venezolanos de Farmacología y Terapéutica
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
